TTrialPathMatch Me to Trials
← Back to trials
RecruitingOsteoarthritis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Eligible age

18+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Sponsor: Eli Lilly and Company

You may qualify if…

  • Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
  • Have tried at least once to lose weight through diet but were unsuccessful
  • Have osteoarthritis of the knee and at least one of the following conditions:
  • Be over 50 years old
  • Have morning knee stiffness that lasts about 30 minutes
  • Have a crackling or grinding sound or feeling in the knee

You may not qualify if…

  • Have gained or lost more than 11 pounds within 90 days prior to screening
  • Have had a surgery for obesity or plan to have one in the next 18 months
  • Have an active knee infection
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure
  • Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening

Where it's recruiting

Arizona

Phoenix · Tempe

California

Huntington Beach · Thousand Oaks

Colorado

Colorado Springs

Connecticut

Waterbury

Georgia

Decatur · Woodstock

Illinois

Chicago

Kansas

Newton

Missouri

City of Saint Peters · Kansas City

New Jersey

Somerset

Source: ClinicalTrials.gov · NCT07153471 · last updated 2026-06-04